61 118

Cited 0 times in

면역학적 고위험도 신장이식 환자에서 Sirolimus와 Tacrolimus 조합:이식 후 3년 추적 관찰 결과

Other Titles
 Sirolimus Combination with Tacrolimus in Kidney Transplant Recipients at High Immunological Risk: Observational Results 3 Years after Transplantation 
Authors
 이주한  ;  송승환  ;  이재근  ;  김범석  ;  허규하  ;  김유선 
Citation
 Journal of the Korean Society for Transplantation (대한이식학회지), Vol.30(4) : 165-171, 2016 
Journal Title
 Journal of the Korean Society for Transplantation  (대한이식학회지) 
ISSN
 1298-1711 
Issue Date
2016
Keywords
Sirolimus ; Tacrolimus ; Kidney transplantation ; Immunosuppression ; Neoplasms
Abstract
Background : The optimal immunosuppressive strategy for renal transplant recipients at high immunological risk requires clarification. We compared the 3 year outcomes of a sirolimus group (tacrolimus plus sirolimus) to those of a control group (tacrolimus plus mycophenolate mofetil). Methods : This observational study was an extension of a prospective pilot study. We assessed acute rejection, glomerular filtration rate, adverse events, graft, and patient survival. Results : Overall, 43% of the sirolimus group versus 78% of the control group were still on the initial immunosuppressive regimen at 3 years (P=0.005), and most discontinuations in each group were due to adverse events. No differences were observed between two groups with respect to acute rejection. The mean glomerular filtration rate at 36 months was greater in the sirolimus group than in the control group, but this was not statistically significant (64.0±6.8 mL/min/1.73 m2 vs. 61.8±17.1 mL/min/1.73 m2,P=0.576). Graft and patient survival were similar in both groups. Importantly, mean tacrolimus through levels were significantly lower in the sirolimus group than in the control group at each time point. No neoplasm was reported in the sirolimus group. In the control group, three cases of neoplasms developed during the study period. Conclusions : The sirolimus group had a greater number of discontinuations, particularly related to adverse events. Nevertheless, optimal concentration of sirolimus allowed reduced calcineurin inhibitor exposure in high immunologic risk patients, without increasing the risk of acute rejection and graft failure.
Files in This Item:
T201605420.pdf Download
DOI
10.4285/jkstn.2016.30.4.165
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
김범석(Kim, Beom Seok) ORCID logo https://orcid.org/0000-0002-5732-2583
김유선(Kim, Yu Seun) ORCID logo https://orcid.org/0000-0002-5105-1567
송승환(Song, Seung Hwan)
이재근(Lee, Jae Geun) ORCID logo https://orcid.org/0000-0002-6722-0257
이주한(Lee, Ju Han)
허규하(Huh, Kyu Ha) ORCID logo https://orcid.org/0000-0003-1364-6989
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152806
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse